O
GHRS icon

OrbiMed’s GH Research GHRS Stock Holding History

OrbiMed’s Portfolio GHRS Stock Details GHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-736,315
Closed -$8.74M – 133
2023
Q2 		$8.74M Sell
736,315
-922,700
-56% -$9.46M 0.16% 93
2023
Q1 		$13.3M Buy
1,659,015
+36,955
+2% +$340K 0.26% 78
2022
Q4 		$15.8M Hold
1,622,060
– – 0.3% 68
2022
Q3 		$18.8K Hold
1,622,060
– – 0.35% 67
2022
Q2 		$16.2K Buy
1,622,060
+193,328
+14% +$2.51M 0.29% 72
2022
Q1 		$26.1M Hold
1,428,732
– – 0.42% 58
2021
Q4 		$33.3M Buy
1,428,732
+66
+0% +$1.45K 0.43% 64
2021
Q3 		$31.5M Hold
1,428,666
– – 0.35% 76
2021
Q2 		$31M Buy
+1,428,666
New +$29.2M 0.31% 76

Other funds holding GHRS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

OrbiMed's GHRS Position: Q3 2023 in Review

OrbiMed sold out of GH Research (GHRS) in Q3 2023, closing a stake of 736,315 shares — an estimated $8.74M sold.

OrbiMed first reported a position in GHRS in Q2 2021 and held it in 9 quarters. The position peaked at $33.3M in Q4 2021. 29 funds tracked by Wall St. Rank hold GHRS as of Q3 2023.

  • OrbiMed reported no remaining GH Research position as of Q3 2023 after selling out during the quarter.
  • OrbiMed sold 736,315 GH Research shares in Q3 2023, an estimated $8.74M.
  • OrbiMed first reported a position in GH Research in Q2 2021 and held it in 9 quarters.
  • OrbiMed's GH Research position peaked at $33.3M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held GH Research as of Q3 2023.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.